This inventor holds 2 USPTO granted patents. Top assignee: University of California. Active years: 2000-2002.
Company Filing History:
Years Active: 2000-2002
Title: Daizong Li: Innovator in Mucin Gene Expression Inhibition
Introduction
Daizong Li is a prominent inventor based in San Francisco, CA. He has made significant contributions to the field of airway disease treatment through his innovative research. With a total of 2 patents, his work focuses on the inhibition of mucin production, which is crucial for addressing various respiratory conditions.
Latest Patents
Li's latest patents include groundbreaking methods for inhibiting MUC-5 mucin gene expression. The first patent details methods for identifying inhibitors of mucin production and outlines approaches for treating airway diseases such as cystic fibrosis, chronic bronchitis, bronchial pneumonia, and asthma. The compositions provided in this patent utilize reporter gene constructs that are inducible by mucomones. The second patent mirrors the first, emphasizing the importance of these methods in combating airway diseases through the inhibition of mucin production.
Career Highlights
Daizong Li is affiliated with the University of California, where he conducts his research. His work has garnered attention for its potential impact on treating chronic respiratory conditions. His innovative approaches have positioned him as a key figure in the field of mucin gene expression research.
Collaborations
Li collaborates with esteemed colleagues such as Erin Gensch and Carol Basbaum. Their combined expertise enhances the research efforts aimed at developing effective treatments for airway diseases.
Conclusion
Daizong Li's contributions to the field of mucin gene expression inhibition are noteworthy. His innovative patents and collaborations reflect his commitment to advancing medical research and improving patient outcomes.